JP2015096072A - 身体活動促進剤 - Google Patents
身体活動促進剤 Download PDFInfo
- Publication number
- JP2015096072A JP2015096072A JP2014248852A JP2014248852A JP2015096072A JP 2015096072 A JP2015096072 A JP 2015096072A JP 2014248852 A JP2014248852 A JP 2014248852A JP 2014248852 A JP2014248852 A JP 2014248852A JP 2015096072 A JP2015096072 A JP 2015096072A
- Authority
- JP
- Japan
- Prior art keywords
- lutein
- milk
- physical activity
- enriched
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000037081 physical activity Effects 0.000 title claims abstract description 79
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 130
- 235000012680 lutein Nutrition 0.000 claims abstract description 130
- 229960005375 lutein Drugs 0.000 claims abstract description 129
- 239000001656 lutein Substances 0.000 claims abstract description 129
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 129
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 129
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 129
- 235000013336 milk Nutrition 0.000 claims abstract description 108
- 239000008267 milk Substances 0.000 claims abstract description 108
- 210000004080 milk Anatomy 0.000 claims abstract description 108
- 230000000694 effects Effects 0.000 claims abstract description 23
- 210000001596 intra-abdominal fat Anatomy 0.000 claims description 37
- 230000001737 promoting effect Effects 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 230000001603 reducing effect Effects 0.000 claims description 10
- 230000006400 anxiety behaviour Effects 0.000 claims description 8
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 230000003449 preventive effect Effects 0.000 abstract description 4
- 229940124597 therapeutic agent Drugs 0.000 abstract description 4
- 239000003638 chemical reducing agent Substances 0.000 description 22
- 235000013305 food Nutrition 0.000 description 18
- 238000012360 testing method Methods 0.000 description 13
- 241000124008 Mammalia Species 0.000 description 11
- 239000003623 enhancer Substances 0.000 description 10
- 210000002027 skeletal muscle Anatomy 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 230000035882 stress Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000037356 lipid metabolism Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 4
- 235000005881 Calendula officinalis Nutrition 0.000 description 4
- 241000736851 Tagetes Species 0.000 description 4
- 235000013793 astaxanthin Nutrition 0.000 description 4
- 239000001168 astaxanthin Substances 0.000 description 4
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 4
- 229940022405 astaxanthin Drugs 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- -1 feed Substances 0.000 description 4
- 235000020256 human milk Nutrition 0.000 description 4
- 210000004251 human milk Anatomy 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 150000002658 luteins Chemical class 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 235000020185 raw untreated milk Nutrition 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000003464 asthenopia Diseases 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000020940 control diet Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000020191 long-life milk Nutrition 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 1
- 235000004911 (-)-epigallocatechin gallate Nutrition 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 101150073133 Cpt1a gene Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 1
- 101001077604 Homo sapiens Insulin receptor substrate 1 Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 206010028311 Muscle hypertrophy Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 108010015181 PPAR delta Proteins 0.000 description 1
- 101150110386 SLC2A4 gene Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 235000020535 bottled fortified water Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- VFSWRBJYBQXUTE-UHFFFAOYSA-N epi-Gallocatechin 3-O-gallate Natural products Oc1ccc2C(=O)C(OC(=O)c3cc(O)c(O)c(O)c3)C(Oc2c1)c4cc(O)c(O)c(O)c4 VFSWRBJYBQXUTE-UHFFFAOYSA-N 0.000 description 1
- 230000037080 exercise endurance Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000002425 internal capsule Anatomy 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 230000012042 muscle hypertrophy Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Abstract
【解決手段】ルテインを強化(添加)した乳を有効成分として含有する身体活動促進剤、より具体的には、ルテインを200μg以上/kgで含有する乳を有効成分とする身体活動促進剤により、前記の課題は解決される。この身体活動促進剤は、生体の身体活動を促進して、身体活動量を増加させることから、生活習慣病の予防剤や治療剤に適用できる。
【選択図】なし
Description
[1] ルテインを強化した乳を有効成分として含有する身体活動促進剤及び/又は内臓脂肪量低減剤。
[2] ルテインを強化した乳がルテインを添加した乳である、前記[1]に記載の身体活動促進剤及び/又は内臓脂肪量低減剤。
[3] ルテインを強化した乳がルテインを摂取した哺乳動物が分泌した乳である、前記[1]に記載の身体活動促進剤及び/又は内臓脂肪量低減剤。
[4] ルテインを強化した乳がルテインを200μg/kg以上で含有する、前記[1] ないし[3]に記載の身体活動促進剤及び/又は内臓脂肪量低減剤。
[5] 前記[1]ないし[4]に記載の身体活動促進剤及び/又は内臓脂肪量低減剤を含有する飲食品、飼料、医薬品。
[6] 前記[3]に記載のルテインを強化した乳を分泌する哺乳動物に摂取させるための、ルテインを含有する飲食品、飼料、医薬品。
[7] ルテインを有効成分とする、乳の身体活動促進作用増強剤及び/又は内臓脂肪量低減作用増強剤。
[8] ルテインを200μg/kg以上で含有する、前記[7]に記載の乳の身体活動促進作用増強剤及び/又は内臓脂肪量低減作用増強剤。
ルテインを20重量%で含有するマリーゴールド色素(ルテイン20、株式会社 協和ウエルネス)を、市販の牛乳(明治おいしい牛乳、明治乳業株式会社)に0.05重量%で添加し、ルテインを0.01重量%で含有する、ルテインを強化した乳(ルテイン強化乳)を製造した。
実施例1のマリーゴールド色素を、実験動物用精製飼料であるAIN−93Gに0.2重量%で添加し、ルテインを強化した乳(ルテイン強化乳)を分泌する母親マウスの摂取用のルテインを強化した飼料(ルテイン強化飼料)を製造した。
実施例1のマリーゴールド色素を、レシチン水溶液(レシチン濃度:0.01重量%)に0.05重量%で添加し、ルテインを0.01重量%で含有する、ルテインを添加したレシチン水溶液(ルテイン強化水)を製造した。
F344ラット雄性の3週令について48匹を用いて、1週間で予備飼育した後に、自発回転走行ケージと通常ケージで飼育する2群に分けた。さらに、水(対照)、比較例1のルテイン強化水(ルテイン濃度:0.01重量%)、牛乳(明治おいしい牛乳、明治乳業株式会社)、実施例1のルテイン強化乳(ルテイン濃度:0.01重量%)を試験試料として、各々に10mL/kg−体重で経口投与する4群に分けて、計8群に組み分けた。試験飼育期間は、毎日17時から翌朝5時まで暗期とし、11時から5時まで食餌を抜いて絶食とし、明期には回転ケージへの移動を阻止して、安静とした。暗期の直前に試験試料をフィーディングチューブで経口投与した後に、新しい餌を与え、30分後から自発回転走行量を測定した。毎日運動量、体重、摂食量を測定し、試験の9週間後に、腹部大動脈から採血し、肝臓、腓腹筋、脂肪組織重量を測定した。血中と肝臓中の中性脂肪、総コレステロール量、被覆筋中のグリコーゲン含量を測定した。さらに、肝臓とヒラメ筋中のAMPK、cpt1、 PPARα、PPARδ、TNFα、FAS、IRS1、IGF1、Glut4などのmRNA発現量をReal-time PCRを用いて測定した。
プラグ確認を0日として妊娠14日目のC57blck/6Jマウスについて、10匹を5匹ずつ恒光群(LL群)と明暗群(DL群)に分け、さらに、各群の3匹には、対照の精製飼料(AIN93)を与え(LL-cont群、LL-cont群)、各群の残りの2匹には、実施例2のルテイン強化飼料を与えた(LL-lutein群、DL-lutein群)。食餌量を制限せずに、飲水ともに自由摂食させた。DL群では、夕方6時半から明朝8時半までを暗期とした。恒光群では、妊娠14日目から、出生日を0日として出生後22日目まで連続して恒光条件下で飼養した。離乳後には、両群とも明暗周期を夕方6時半から明朝6時半までを暗期とする通常の飼養条件とした。
Claims (12)
- ルテインを乳に添加することにより、不安行動抑制作用を乳に付与又は増強する方法。
- ルテインを乳に添加することにより、身体活動正常化効果を乳に付与する方法。
- 身体活動正常化効果がストレス条件下での効果である、請求項2に記載の方法。
- ルテインを乳に添加することにより、身体活動促進効果を乳に付与又は増強する方法。
- ルテインを乳に添加することにより、さらに、内臓脂肪量低減効果を乳に付与又は増強する、請求項4に記載の方法。
- 80μg/kg以上でルテインを乳に添加する、請求項1〜5のいずれか1項に記載の方法。
- 不安行動抑制作用が付与又は増強された乳を製造するためのルテインの使用。
- 身体活動正常化効果が付与された乳を製造するためのルテインの使用。
- 身体活動正常化効果がストレス条件下での効果である、請求項8に記載の使用。
- 身体活動促進効果が付与又は増強された乳を製造するためのルテインの使用。
- さらに、内臓脂肪量低減効果が付与又は増強された前記乳を製造するための請求項10に記載の使用。
- 80μg/kg以上でルテインを乳に添加する、請求項7〜11のいずれか1項に記載の使用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014248852A JP6071988B2 (ja) | 2014-12-09 | 2014-12-09 | 身体活動促進剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014248852A JP6071988B2 (ja) | 2014-12-09 | 2014-12-09 | 身体活動促進剤 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009216482A Division JP2011063552A (ja) | 2009-09-18 | 2009-09-18 | 身体活動促進剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015096072A true JP2015096072A (ja) | 2015-05-21 |
JP6071988B2 JP6071988B2 (ja) | 2017-02-01 |
Family
ID=53373706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014248852A Active JP6071988B2 (ja) | 2014-12-09 | 2014-12-09 | 身体活動促進剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6071988B2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021065664A1 (ja) * | 2019-10-04 | 2021-04-08 | サントリーホールディングス株式会社 | 生活活動量の維持、低下予防、低下抑制又は改善用組成物 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61181338A (ja) * | 1985-02-07 | 1986-08-14 | Katsuhiko Miyaji | 緑汁含有牛乳又は豆乳の製造法 |
JPH09124470A (ja) * | 1995-10-26 | 1997-05-13 | Suntory Ltd | 抗ストレス組成物 |
JP2002065212A (ja) * | 2000-08-29 | 2002-03-05 | Meiji Seika Kaisha Ltd | 筋強化用食品組成物及び筋強化剤 |
JP2003095930A (ja) * | 2001-09-20 | 2003-04-03 | Kagome Co Ltd | 抗肥満剤 |
US20030113408A1 (en) * | 1998-12-29 | 2003-06-19 | Clark George H. | Carbonated fortified milk-based beverage and method for suppressing bacterial growth in the beverage |
WO2007142230A1 (ja) * | 2006-06-09 | 2007-12-13 | Morinaga Milk Industry Co., Ltd. | 脂質代謝改善剤 |
JP2009507044A (ja) * | 2005-09-09 | 2009-02-19 | マレー ゴールバーン コーオペラティブ コー リミテッド | 乳由来組成物、及び筋肉量または筋力を増強するための使用 |
WO2009037562A2 (en) * | 2007-09-19 | 2009-03-26 | Ophthalmopharma Ag | Nutritional supplement formulations and fortified foods comprising such supplements |
JP2009513641A (ja) * | 2005-10-26 | 2009-04-02 | アボット・ラボラトリーズ | ドコサヘキサエン酸およびルテインを含有する乳児用製剤 |
-
2014
- 2014-12-09 JP JP2014248852A patent/JP6071988B2/ja active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61181338A (ja) * | 1985-02-07 | 1986-08-14 | Katsuhiko Miyaji | 緑汁含有牛乳又は豆乳の製造法 |
JPH09124470A (ja) * | 1995-10-26 | 1997-05-13 | Suntory Ltd | 抗ストレス組成物 |
US20030113408A1 (en) * | 1998-12-29 | 2003-06-19 | Clark George H. | Carbonated fortified milk-based beverage and method for suppressing bacterial growth in the beverage |
JP2002065212A (ja) * | 2000-08-29 | 2002-03-05 | Meiji Seika Kaisha Ltd | 筋強化用食品組成物及び筋強化剤 |
JP2003095930A (ja) * | 2001-09-20 | 2003-04-03 | Kagome Co Ltd | 抗肥満剤 |
JP2009507044A (ja) * | 2005-09-09 | 2009-02-19 | マレー ゴールバーン コーオペラティブ コー リミテッド | 乳由来組成物、及び筋肉量または筋力を増強するための使用 |
JP2009513641A (ja) * | 2005-10-26 | 2009-04-02 | アボット・ラボラトリーズ | ドコサヘキサエン酸およびルテインを含有する乳児用製剤 |
WO2007142230A1 (ja) * | 2006-06-09 | 2007-12-13 | Morinaga Milk Industry Co., Ltd. | 脂質代謝改善剤 |
WO2009037562A2 (en) * | 2007-09-19 | 2009-03-26 | Ophthalmopharma Ag | Nutritional supplement formulations and fortified foods comprising such supplements |
Non-Patent Citations (4)
Title |
---|
JPN6015046693; ROODENBURG, A.J. et al.: '"Amount of fat in the diet affects bioavailability of lutein esters but not of alpha-carotene, beta-' AM. J. CLIN. NUTR. Vol.71, No.5, 2000, pp.1187-1193 * |
JPN6015046695; GRUBER, M. et al.: '"Correlates of serum lutein + zeaxanthin: findings from the Third National Health and Nutrition Exam' J. NUTR. Vol.134, No.9, 200409, pp.2387-2394 * |
JPN6015046698; ROCK, C.L. et al.: '"Diet and lifestyle correlates of lutein in the blood and diet."' J. NUTR. Vol.132, No.3, 200203, pp.525S-530S * |
JPN6015046699; 松井崇、外7名: '「アスタキサンチンは運動トレーニングによる抗不安・抗うつ効果を増強する」' 日本体育学会大会予稿集 60th, 20090826, p.133 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021065664A1 (ja) * | 2019-10-04 | 2021-04-08 | サントリーホールディングス株式会社 | 生活活動量の維持、低下予防、低下抑制又は改善用組成物 |
Also Published As
Publication number | Publication date |
---|---|
JP6071988B2 (ja) | 2017-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200108040A1 (en) | Agent for improving brain function and agent for preventing or treating cognitive impairment | |
CN113575686B (zh) | 提高免疫力的营养组分及含有其的食品或保健品和应用 | |
WO2011096414A1 (ja) | ミトコンドリア機能向上剤 | |
CN102389053A (zh) | 一种低胆固醇、富硒、富胡萝卜素鸡蛋的生产方法 | |
CN102753183A (zh) | 运动功能改善剂 | |
JP7032855B2 (ja) | 時計遺伝子の発現を変化させるための組成物 | |
JP6869286B2 (ja) | 桂皮アルデヒド及び亜鉛を含む組成物並びにかかる組成物の使用方法 | |
JP6265335B2 (ja) | 骨密度増加剤、破骨細胞活性抑制剤及び骨リモデリング改善剤 | |
JP2016008180A (ja) | 筋肉持久力向上剤 | |
JP6127545B2 (ja) | ガレート型カテキンとタンパク質との複合体およびカフェインを含む抗肥満組成物の製造方法 | |
JPS5832867B2 (ja) | リゾチ−ム並びにヨウ素分を高濃度に含有する卵 | |
CN104543348A (zh) | 一种低胆固醇、富胡萝卜素、富ala鸡蛋的生产方法 | |
JP6071988B2 (ja) | 身体活動促進剤 | |
CN104431304A (zh) | 一种低胆固醇、富铁、富dha鸡蛋的生产方法 | |
JP2011063552A (ja) | 身体活動促進剤 | |
JP2018503605A (ja) | ヒト機能性食品用の25−ヒドロキシビタミンdおよび酸化防止剤/抗炎症剤の組み合わせ | |
CN104430143A (zh) | 一种低胆固醇、富胡萝卜素、富dha鸡蛋的生产方法 | |
CN104543426A (zh) | 一种低胆固醇、富维生素e、富ala鸡蛋的生产方法 | |
CN105248944A (zh) | 一种富钾、富胡萝卜素鸡蛋的生产方法 | |
RU2684331C1 (ru) | Способ стимуляции продуктивности и гемопоэза у кроликов при одновременном улучшении вкусовых качеств мяса | |
RU2767609C1 (ru) | Способ повышения биологической ценности мяса кроликов путем увеличения содержания в нем количества незаменимых аминокислот | |
CN109153693A (zh) | 安全-稳定的缩醛磷脂和其制剂及认知症的未病状态的判断方法 | |
CN105581012A (zh) | 一种富dha鸡蛋的生产方法 | |
CN104431400A (zh) | 一种低胆固醇、富维生素a、富dha鸡蛋的生产方法 | |
JP2000302677A (ja) | カルニチン自己産生能改善作用を有する医薬および食品・飼料組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150107 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20151030 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160607 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160805 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161206 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161227 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6071988 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |